

University of Groningen

Tumor immunology in ovarian cancer

Merkus-Brunekreeft, Kim

DOI:
[10.33612/diss.147014180](https://doi.org/10.33612/diss.147014180)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2020

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):
Merkus-Brunekreeft, K. (2020). *Tumor immunology in ovarian cancer*. [Thesis fully internal (DIV), University of Groningen]. University of Groningen. <https://doi.org/10.33612/diss.147014180>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Stellingen

Behorende bij het proefschrift

Tumor immunology in ovarian cancer

1. A lack of T cell activation in ovarian cancer tumor draining lymph nodes might explain the relatively poor response of ovarian cancer patients to current immunotherapeutic strategies.
This thesis; chapter 2.
2. CD103⁺ tumor infiltrating T cells in high-grade serous ovarian cancer are possible targets for (dual) immune checkpoint inhibition.
This thesis; chapter 3.
3. For optimal treatment results immunotherapies have to be combined with the current standard of care for ovarian cancer.
This thesis; chapter 4.
4. Strategies to upregulate MHC-I during/after neoadjuvant chemotherapy may improve treatment outcome in ovarian cancer patients.
This thesis; chapter 4.
5. Targeted delivery of CD40L to cancer cells is a potential immunotherapeutic strategy and should be tested in vivo.
This thesis; chapter 5.
6. Personalized tumor-specific cancer treatment is changing the way we look at ovarian cancer.
This thesis; chapter 6.
7. Immune profiling of patients' tumors enables us to treat every person equally but different.
This thesis; chapter 6.
8. When I started counting my blessings, my whole life turned around.
Willie Nelson.
9. Cooking is science, throw some ingredients together and a meal may appear, may not be edible but everyone has to start somewhere.
Alton brown.
10. Geef mij werk dat bij me past en ik hoef nooit meer te werken.
Confucius.
11. Twijfelen is een goed begin van een carrière in de wetenschap.
Loesje.